Fact based stock research
Augmedix (NasdaqCM:AUGX)
US05105P1075
How to read the free ranks
For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".
Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".
Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.
Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.
(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).
(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.
Latest Obermatt Ranks
Log in or sign up to see the new 360° View and Sentiment ranks.
Country | USA |
Industry | Health Care Technology |
Index | NASDAQ |
Size class | X-Small |
. Stock data may be delayed. Log in or sign up to get the most recent research.
Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.
It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.
Review the performance ranks of the individual metrics that form each investment strategy.
Research History: Augmedix
RESEARCH HISTORY | 2021 | 2022 | 2023 | 2024 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | n/a |
|
67 |
|
12 |
|
n/a |
|
GROWTH | ||||||||
GROWTH | n/a |
|
39 |
|
95 |
|
n/a |
|
SAFETY | ||||||||
SAFETY | n/a |
|
7 |
|
15 |
|
n/a |
|
SENTIMENT | ||||||||
SENTIMENT | n/a |
|
73 |
|
33 |
|
new | |
360° VIEW | ||||||||
360° VIEW | n/a |
|
35 |
|
22 |
|
new |
Combined financial peformance in Detail
n/a n/aRESEARCH HISTORY | 2021 | 2022 | 2023 | 2024 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | n/a |
|
67 |
|
12 |
|
n/a |
|
GROWTH | ||||||||
GROWTH | n/a |
|
39 |
|
95 |
|
n/a |
|
SAFETY | ||||||||
SAFETY | n/a |
|
7 |
|
15 |
|
n/a |
|
COMBINED | ||||||||
COMBINED | n/a |
|
15 |
|
28 |
|
n/a |
|
Value Metrics in Detail
n/a n/aVALUE METRICS | 2021 | 2022 | 2023 | 2024 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | n/a |
|
51 |
|
30 |
|
n/a |
|
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | n/a |
|
56 |
|
56 |
|
n/a |
|
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | n/a |
|
94 |
|
1 |
|
n/a |
|
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | n/a |
|
1 |
|
1 |
|
n/a |
|
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | n/a |
|
67 |
|
12 |
|
n/a |
|
Growth Metrics in Detail
n/a n/aGROWTH METRICS | 2021 | 2022 | 2023 | 2024 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | n/a |
|
85 |
|
94 |
|
n/a |
|
PROFIT GROWTH | ||||||||
PROFIT GROWTH | n/a |
|
33 |
|
53 |
|
n/a |
|
CAPITAL GROWTH | ||||||||
CAPITAL GROWTH | n/a |
|
7 |
|
100 |
|
n/a |
|
STOCK RETURNS | ||||||||
STOCK RETURNS | n/a |
|
39 |
|
99 |
|
n/a |
|
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | n/a |
|
39 |
|
95 |
|
n/a |
|
Safety Metrics in Detail
n/a n/aSAFETY METRICS | 2021 | 2022 | 2023 | 2024 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | n/a |
|
11 |
|
10 |
|
n/a |
|
REFINANCING | ||||||||
REFINANCING | n/a |
|
30 |
|
32 |
|
n/a |
|
LIQUIDITY | ||||||||
LIQUIDITY | n/a |
|
10 |
|
34 |
|
n/a |
|
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | n/a |
|
7 |
|
15 |
|
n/a |
|
Sentiment Metrics in Detail
SENTIMENT | 2021 | 2022 | 2023 | 2024 | ||||
---|---|---|---|---|---|---|---|---|
ANALYST OPINIONS | ||||||||
ANALYST OPINIONS | n/a |
|
92 |
|
74 |
|
new | |
OPINIONS CHANGE | ||||||||
OPINIONS CHANGE | n/a |
|
96 |
|
83 |
|
new | |
PRO HOLDINGS | ||||||||
PRO HOLDINGS | n/a |
|
3 |
|
14 |
|
new | |
MARKET PULSE | ||||||||
MARKET PULSE | n/a |
|
50 |
|
15 |
|
new | |
CONSOLIDATED RANK: SENTIMENT | ||||||||
CONSOLIDATED RANK: SENTIMENT | n/a |
|
73 |
|
33 |
|
new |
Free stock analysis by the purely fact based Obermatt Method for Augmedix from September 26, 2024.
Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.